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Acute kidney injury (AKI) is a complication of critical illness 
that affects up to 50% of intensive care patients.1-3 The 
use of renal replacement therapy has evolved as the 
treatment for severe AKI, and is required in up to 5–6% 
of all critically ill patients in intensive care units (ICUs).4 
Continuous renal replacement therapy (CRRT) is the most 
common dialytic therapy used to treat AKI worldwide.5 
CRRT techniques are instituted by clinicians with the aim of 
achieving homeostasis of water, electrolytes, acid base and 
removal of waste products in this group of patients.6 Solute 
control and maintenance have long been key priorities in 
the provision of CRRT and has been an area of research 
and focus since the fi rst Acute Dialysis Quality Initiative 
consensus meeting.7,8 Subsequently, two large multicentre 
randomised controlled trials defi nitively showed that there 
was no survival benefi t in increasing the dose of CRRT from 
the common dose of 25 mL/kg/h.9,10
While a greater CRRT dose does not lead to improved 
patient outcomes, solute removal (particularly small solutes, 
such as urea and creatinine) remains an important aim of 
the therapy. For prescribing CRRT, clinicians continue to 
target a prescription dose and best settings to achieve solute 
removal for each 24-hour period, to remove excessive toxins 
and maintain solute balance for each individual patient.8 In 
addition to a prescribed effl uent rate, other clinical variables 
may contribute to solute clearance in CRRT, including “down 
time”, membrane composition, membrane fouling and 
frequent circuit clotting.11 The Acute Dialysis Quality Initiative 
has recently recommended research objectives aimed at 
identifying optimal techniques and practical prescriptions 
for solute removal.8 Blood fl ow rate (BFR) and a modality 
of CRRT — that is, continuous venovenous haemofi ltration 
(CVVH), continuous venovenous haemodialysis (CVVHD) or 
continuous venovenous haemodiafi ltration (CVVHDF) — are 
two common bedside prescriptions that may have a direct 
impact on solute removal, but have not been assessed in 
any randomised controlled study. An increase in BFR in 
convective modes, such as CVVH, may directly assist solute 
removal by increasing transmembrane pressure, exposing 
additional plasma water to the dialyser per effl uent dose 
and assisting solvent drag across the membrane. Indirectly, 
a faster BFR may decrease blood viscosity in the membrane, 
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ABSTRACT
Objective: To determine if faster blood fl ow rate (BFR) 
has an effect on solute maintenance in continuous renal 
replacement therapy.
Design: Prospective randomised controlled trial.
Setting: 24-bed, single centre, tertiary level intensive care 
unit.
Participants: Critically ill adults requiring continuous renal 
replacement therapy (CRRT).
Interventions: Patients were randomised to receive one of 
two BFRs: 150 mL/min or 250 mL/min.
Main outcome measures: Changes in urea and creatinine 
concentrations (percentage change from baseline) and 
delivered treatment for each 12-hour period were used to 
assess solute maintenance.
Results: 100 patients were randomised, with 96 
completing the study (49 patients, 150 mL/min; 47 
patients, 250 mL/min). There were a total of 854 12-hour 
periods (421 periods, 150 mL/min; 433 periods, 250 mL/
min). Mean hours of treatment per 12 hours was 6.3 hours 
(standard deviation [SD], 3.7) in the 150 mL/min group, 
and 6.7 hours (SD, 3.9) in the 250 mL/min group (P = 0.6). 
There was no difference between the two BFR groups for 
change in mean urea concentration (150 mL/min group, 
–0.06%; SD, 0.015; v 250 mL/min group, –0.07%; SD, 
0.01; P = 0.42) or change in mean creatinine concentration 
(150 mL/min, –0.05%; SD, 0.01; v 250 mL/min, –0.08%; 
SD, 0.01; P = 0.18). Independent variables associated with 
a reduced percentage change in mean serum urea and 
creatinine concentrations were low haemoglobin levels 
(–0.01%; SD, 0.005; P = 0.002; and 0.01%; SD, 0.005; 
P = 0.006, respectively) and less hours treated (–0.023%; 
SD, 0.001; P = 0.000; and –0.02%; SD, 0.002; P = 0.001, 
respectively). No effect for bodyweight was found.
Conclusions: Faster BFR did not affect solute control 
in patients receiving CRRT; however, differences in urea 
and creatinine concentrations were infl uenced by serum 
haemoglobin and hours of treatment.
Crit Care Resusc 2018; 20 (1): 41-47
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increase fi ltration fraction and decrease membrane fouling 
with eventual clotting. In diffusive modes, such as CVVHD 
and CVVHDF, faster BFR may assist with solute removal 
by maximising concentration gradients between blood 
(plasma) fl ow and dialysate fl ow rates, decreasing dwell 
time and sustaining diffusive movement of solutes across 
the membrane.12
We aimed to test our hypothesis that faster BFR increases 
small solute removal (eg, urea and creatinine) in critically ill 
patients receiving CRRT. To address this question, we report 
additional fi ndings from our recently published randomised 
controlled trial comparing two BFRs and the effect on circuit 
life in patients treated with CRRT.13
Methods
Trial design and setting
This study was a prospective, parallel group randomised 
controlled trial conducted in a 24-bed, adult, tertiary 
referral ICU in Melbourne, Victoria, Australia. The study 
was registered at the Australian New Zealand Clinical Trials 
Registry (ACTRN: 12615001353583) and approved by 
Austin Health Human Research Ethics Committee (HREC 
project no. H2012/04772). Written informed consent from 
the patient or their next of kin was obtained before or soon 
after enrolment.
Eligibility criteria
Critically ill patients in ICU were eligible for the study if they 
fulfi lled the following criteria:
• age ≥ 18 years; and
• AKI (RIFLE [risk of renal dysfunction, injury to the kidney, 
failure of kidney function, loss of kidney function, and 
end-stage kidney disease] classifi cation = F)14 requiring 
CRRT.
• Patients were considered ineligible for the study if they 
fulfi lled any exclusion criterion:
• required citrate anticoagulation (citrate protocol requires 
a set BFR of 150 mL/min); or
• expected to stay in the ICU for < 24 hours.
Interventions
The study compared two BFR settings and the effect on 
small solute control in CRRT. BFR was either 250 mL/min 
or 150 mL/min using CVVH and CVVHDF modes. Vascular 
access was either Niagara 13.5 Fr catheter (24 cm) (Bard, 
Murray Hill, NJ, USA) or GamCath Dolphin Protect 13.0 Fr 
catheter (25 cm) (Gambro, Hechingen, Germany) dual lumen 
catheters. Machines used were Prismafl ex with AN69 ST 
(ST100) 1.0 m2 membrane (Gambro Nephral TM, Lund, 
Sweden) or Infomed HF440 with DF140 Polyethersulfone 
1.4 m2 membrane (Infomed, Geneva, Switzerland) for all 
treatments respectively. We used bicarbonate buffered 
replacement and dialysis fl uid (Baxter, Castlebar, Co. Mayo, 
Ireland). In CVVH, the replacement fl uid was delivered into 
the extracorporeal circuit before and after the fi lter (pre- 
and post-dilution), with a ratio of 50% pre-dilution and 
50% post-dilution. The dose in CVVH was standardised at 
2000 mL/h. In CVVHDF, the replacement fl uid was delivered 
100% post-dilution. The dose in CVVHDF was standardised 
at 1000 mL/h replacement and 1000 mL/h dialysate. CRRT 
was prescribed by the treating intensivist and provided by 
ICU nurses.
Data collection
We collected baseline data regarding age, gender, weight, 
body mass index (BMI), source of admission, severity of 
illness (APACHE [Acute Physiology and Chronic Health 
Evaluation] II and III score; SAPS [Simplifi ed Acute Physiology 
Score] II), diagnostic group, presence of sepsis, mechanical 
ventilation, inotropes and vasopressors, and basic laboratory 
variables pertaining to renal function.
Outcome measurements
For all patients, twice-daily (0500 and 1700 hours) 
measurement of haemoglobin and biochemistry (serum 
creatinine and urea) was performed. The primary outcome 
was small solute maintenance estimated by the change 
in urea and creatinine concentrations over these two 
predefi ned 12-hour periods each day (percentage of change 
in serum levels over time). Circuit life was documented for 
each CRRT circuit as cumulative hours, so that delivered 
treatment hours could be calculated for each 12-hour 
period (T1, 0500–1700 hours; and T2, 1700–0500 hours).
Randomisation
Patients were screened and entered into the study by 
ICU clinical staff. Patients were assigned randomly with 
stratifi cation for modality. Once the treating physician 
prescribed CRRT and the mode of therapy, patients were 
randomised using a web-based central randomisation 
service (Griffi th University Clinical Trial Coordinating Centre). 
A variable block randomisation with parallel allocation was 
software-generated, with inbuilt concealment to allocate 
participants to each study group (150 mL/min v 250 mL/
min). Patients stayed in the treatment group allocated 
at randomisation and modality (CVVH or CVVHDF) for 
treatment throughout their ICU  stay. The sample size was 
without power calculation, was of convenience and was 
associated with the primary investigation.13
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Data analysis
Linear regression analysis was performed to identify 
independent variables that may be associated with change 
in small solute serum levels. Independent variables included 
modality of CRRT, gender, BMI, weight, haemoglobin level 
and number of hours treated in each 12-hr period. Repeated 
measures analysis of variance (ANOVA) was used on the 
independent variables showing signifi cance. The advantage 
of this model is that it considers within-subject measures 
over multiple time points. In this study, patients contributed 
multiple 12-hour periods measuring solute percentage change 
over these periods. Data lacking normality of distribution are 
presented as median with interquartile range (IQR) (25% 
and 75%), using the Wilcoxon rank sum test or mean with 
standard deviation (SD) when normally distributed, and using 
the Student t test, 2 test and the Fisher exact test. A P < 0.5 
was considered signifi cant. SPSS Statistics 21.0 (IBM, Chicago 
IL, USA) software was used for all data analysis.
Results
Participants and recruitment
All patients receiving CRRT in the study ICU (n = 135) were 
screened for eligibility between June 2013 and August, 
2014. From this screening, 100 patients were considered 
Figure 1. CONSORT diagram for patient enrolment
CONSORT = Consolidated 
Standards of Reporting 
Trials. CRRT = continuous 
renal replacement therapy. 
CVVH = continuous 
venovenous haemofi ltration. 
CVVHDF = continuous 
venovenous 
haemodiafi ltration.
eligible and randomised to the study; and two patients 
from each group were randomised but did not receive 
CRRT. Figure 1 shows the CONSORT diagram for patient 
enrolment. Overall, 96 patients (49 in the 150 mL/min 
group, and 47 in the 250 mL/min group) contributed a 
total of 854 12-hour treatment interval periods (421 in the 
150 mL/min group, and 433 in the 250 mL/min group). Of 
the patients studied, 50 received CVVH compared with 46 
treated with CVVHDF.
At randomisation, patients were similar with respect to 
age, sex, severity of illness scores (APACHE II and III; SAPS II), 
admission source and diagnosis (Table 1). There was a slight 
weight difference, with patients in the 150 mL/min group 
being heavier (P = 0.03); however, BMI was similar for both 
groups. Pre-randomisation renal function was also similar 
for both groups.
Primary outcomes: solute maintenance
A total of 7745.5 treatment hours were recorded from 
both groups (3840.7 hours in the 150 mL/min group, and 
3904.8 hours in the 250 mL/min group) (Table 2). The 
mean treatment hours for each 12-hour period was similar 
(150 mL/min group; 6.3 hours; SD, 3.7; 52.5%, v 250 mL/
min group; 6.7 hours; SD, 3.9; 55.8%; P = 0.6) as well as 
total number of 12-hour periods for each BFR group (Table 
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Table 1. Baseline demographic and clinical characteristics*
Admission variables
150 mL/min 
(n = 49)
250 mL/min 
(n = 47) P 
Age 61.08 ± 15.96 60.77 ± 18.31 0.93
Gender (male/female) 34/49 (69%) 24/47 (51%) 0.10
BMI 29.01 ± 5.48 27.59 ± 6.85 0.26
Weight 85.19 ± 20.39 75.85 ± 20.30 0.03
APACHE II 22.16 ± 6.47 23.13 ± 6.55 0.47
APACHE III 85.65 ± 23.17 87.21 ± 26.28 0.76
SAPS II 56.22 ± 14.19 55.55 ± 15.21 0.82
Source of admission
 ED 13 (27.7%) 12 (25.5%)
 Ward 17 (34.7%) 17 (36.2%)
 Post-operative (elective) 7 (14.3%) 6 (12.8%)
 Post-operative (emergency) 5 (10.2%) 4 (8.5%)
 Transfer from other ICU 5 (10.2%) 5 (10.6%)
 Transfer from other hospital 2 (4.1%) 3 (6.4%)
Admission diagnosis
 Cardiovascular 6 (12.2%) 5 (10.6%)
 Cardiac surgery 11 (22.4%) 8 (17.0%)
 Respiratory 0 1 (2.1%)
 Gastrointestinal 6 (12.2%) 6 (12.8%)
 Liver failure 5 (10.2%) 6 (12.8%)
 Liver transplant 10 (20.4%) 13 (27.7%)
 Acute renal failure/
 genitourinary disorder
5 (10.2%) 5 (10.6%)
 Haematological 4 (8.2%) 1 (2.1%)
 Infection/abscess 2 (4.1%) 2 (4.3%)
Mechanical ventilation 41 (83.7%) 36 (76.6%) 0.44
Vasopressor/inotrope 41 (83.7%) 41 (87.2%) 0.77
Severe sepsis 24/49 (49.0%) 26/47 (55.3%) 0.55
Laboratory data before 
randomisation
 Serum creatinine 317.20 ± 171.61 297 ± 181.54 0.16
 Serum urea 23.62 ± 14.94 21.19 ± 10.03 0.33
APACHE = Acute Physiology and Chronic Health Evaluation. BMI = body 
mass index. ED = emergency department. ICU = intensive care unit. 
SAPS = Simplifi ed Acute Physiology Score. * Independent t test and 2 test.
Table 2. Continuous renal replacement therapy treatment times and solute levels
150 mL/min 250 mL/min
CVVH CVVHDF CVVH CVVHDF
12-hour time periods 169 252 261 172
Total treatment time (hours) 1527.7 2313 2331.3 1573.5
Hours of treatment (12-hour periods); mean (SD) 6.3 (3.7) 6.7 (3.9)
Urea level, mmol/L
T1 (0500–1700); mean (SD) 15.7 (7.6) 16.7 (8.7) 13.2 (5.9) 13.1 (6.2)
T2 (1700–0500); mean (SD) 15.2 (7.5) 16.4 (7.7) 12.7 (5.2) 13.4 (6.1)
Creatinine level, µmol/L
T1 (0500–1700); mean (SD) 217.0 (127.3) 226.7 (152.7) 167.8 (82.8) 209.1 (126.2)
T2 (1700–0500); mean (SD) 218.3 (144.9) 216.6 (118.8) 165.0 (87.1) 202.3 (102.9)
CVVH = continuous venovenous haemofi ltration. CVVHDF = continuous venovenous haemodiafi ltration. min = minute. SD = standard deviation
2). The median number of 12-hour periods per patient 
was also similar for both groups (150 mL/min; 6; IQR, 
4–12; v 250 mL/min; 7; IQR, 4.5–12; P = 0.4).
Blood plasma concentrations of urea and creatinine 
were similar for time interval (T1 and T2), BFR and 
modality (Table 2). Linear regression analysis showed 
no difference in the change in urea and creatinine 
concentrations for BFR groups, modality of CRRT, 
gender, BMI and weight. Repeated measures analysis 
of variance (ANOVA) revealed no difference between 
the two BFR groups for change in mean urea 
concentration (150 mL/min; –0.06%; SD, 0.015; v 
250 mL/min; –0.07%; SD, 0.01; P = 0 .42) (Figure 2) 
or change in mean creatinine concentration (150 mL/
min; –0.05%; SD, 0.01; v 250 mL/min; –0.08%; SD, 
0.01; P = 0.18) (Figure 3) There was a signifi cant 
correlation between the 12-hourly percentage change 
in the serum concentration of these two small solutes, 
with decreased haemoglobin levels (150 mL/min; 
–0.01%; SD, 0.005; P = 0.002; v 250 mL/min; 0.01%; 
SD, 0.005; P = 0.006) and less hours of CRRT during 
the 12-hour period (eg, more down time) (150 mL/
min; –0.023%; SD, 0.001; P = 0.000; v 250 mL/min; 
–0.02%; SD, 0.002; P = 0.001).
Discussion
Key fi ndings
In a cohort of 96 patients requiring CRRT, three key 
fi ndings have been identifi ed. First, analysis of the 
data from this study failed to support the hypothesis 
that faster BFR would improve small solute clearance. 
Second, there was an association with number of 
hours treated with CRRT and change in serum solute 
levels. Third, lower serum haemoglobin levels are an 
independent factor associated with difference in urea 
and creatinine levels.
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Relationship to previous studies
The effi ciency of solute removal in CRRT has been a key focus 
since it started to be used for treating critically ill patients with 
AKI.15,16 Foundation studies for small solute removal in CRRT 
were often unable to report BFR, as this was determined 
by arterial blood pressure in continuous arteriovenous 
circuits or as a low fi xed rate (100 mL/min) determined 
by primitive blood pumps in the fi rst venovenous circuits. 
These early reports identifi ed that effl uent rates (dialysate or 
ultrafi ltration rates) were the most important determinants 
of small solute removal, as the volume of effl uent would 
approximate the clearance.15,16 Today, despite signifi cant 
advances in CRRT technology, dosing or solute clearance in 
CRRT is still expressed as total effl uent volume per weight 
and unit of time (mL/kg/h),11 indicating that other factors 
may be less important in the clearance of solutes across the 
semi-permeable membrane.
One aspect of CRRT technology that has changed over 
time is clinicians prescribing a faster BFR. A recent survey 
of Australian and New Zealand ICUs indicated a BFR of 
150–200 mL/min was the dominant setting; however, 
faster rates of 200–250 mL/min were now commonplace 
in the ICUs surveyed.17 Observational studies and recent 
worldwide practice surveys of CRRT also show great 
variability in practice, from 80 mL/min18 to 350 mL/min.19,20 
The prescription of BFR in intermittent haemodialysis (IHD) 
has long been seen as integral to therapy prescription for 
dosing (solute removal) in direct relation to dialysate fl ow 
rates, and is well established and standardised for the 
treatment of chronic kidney disease with dialysis.21 Blood 
fl ow rates of ≥ 300 mL/min are prescribed typically with 
matching or higher dialysate fl ow rates (300–500 mL/min) 
to achieve azotemic control in this group of patients.22,23 
One key important difference between IHD and CRRT is the 
ability to achieve higher BFR during IHD with the use of long 
term large bore vascular access catheters and arteriovenous 
shunts, which both allow high BFR prescriptions aimed at 
targeted dosing regimens accordingly.
Historically, the prescription of BFR in CRRT has been 
based on the experience gained from IHD therapies, and 
a BFR of 200 mL/min has been common without any 
evidence for this.24,25 However, limiting factors for blood 
fl ow in CRRT have been the use of short term small bore 
catheters in haemodynamically unstable patients26 and the 
machine technology used to pump venous blood through 
the extracorporeal circuit. Unlike IHD, the setting of BFR 
in CRRT has been focused towards extracorporeal circuit 
patency and prevention of premature clotting (eg, < 6 
hours) of the circuit.13,19,27 The prescription of faster BFR in 
recent times may be attributed to improvements in vascular 
access catheters and machine capability rather than concern 
for solute clearance.
One retrospective review of 15 patients has examined any 
association with blood fl ow rates and clearances of urea and 
creatinine concentrations in CVVHDF.28 Four BFR groupings 
were audited, with a mean rate of 125 mL/min that ranged 
between 35 mL/min and 175 mL/min. A comparative fi nding 
was that a BFR of 135–145 mL/min showed a difference in 
urea and creatinine concentrations compared with lower 
BFR ranges in this mode of CRRT. Consistent with our 
fi ndings, Gilbert and colleagues28 report that differences 
in change in urea and creatinine concentrations were best 
predicted by number of hours treated.
The acronym CRRT suggests that therapy is continuous 
and without interruption; however, down time and failure 
occurs frequently.29 Reasons for interruptions to treatment 
are clotting, or when the patient requires procedures 
outside the ICU, or when native assessment of kidney 
function is trialled.30 In this study, we identifi ed an effective 
treatment time approximating 50% (6.3 hours and 6.7 
hours/12 hours). The delivery therapy time is similar, with 
previously reported prescription versus delivery data.24-33 
Figure 2. Urea change by grouping (repeated 
measures analysis of variance [ANOVA])
Figure 3. Creatinine change by grouping (repeated 
measures analysis of variance [ANOVA])
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Similar to this study, it has also been shown that there is a 
direct correlation between reduction in hours of treatment 
and loss of small solute control in critically ill patients.11,29,31 
While there has been comparative prescribed versus actual 
delivered dose and therapy reports, it remains unclear which 
is the optimal number of CRRT hours per day to maintain 
small solute control in this group of patients. However, there 
is recent acknowledgement that clinicians who prescribe 
CRRT should be aware of the effect of delivery time in 
comparison to prescribed treatment, and should form an 
integral quality indicator measure in process reassessment, 
monitoring, reporting and benchmarking for CRRT.34
Based on the results identifi ed in this study, we suggest 
that the number of hours of active treatment should 
be routinely reviewed as a component of practice. This 
information should be reviewed twice daily and then be 
considered in the context of solute levels and planned 
activities that might lead to down time, with CRRT 
prescriptions altered accordingly.
In this study, we report that low serum haemoglobin 
levels are an independent variable that affects small solute 
removal. Patients with lower serum haemoglobin count 
showed a smaller reduction in serum urea and creatinine 
levels over a 12-hour period. To our knowledge, this is the 
fi rst study to report such fi nding. 
Strengths and limitations
This randomised controlled trial of 100 patients presents, 
for the fi rst time, an investigation into the effect of BFR 
on solute maintenance in two commonly used modes of 
CRRT. The analysis is based on 7745 hours (> 300 days) 
of treatment time. This number of patients and treatment 
time is representative of a tertiary level ICU and provides 
important fi ndings for current CRRT practice. The study 
has some limitations. Solute clearance was reported as 
the percentage change in serum level over time. A direct 
measurement of serum solute levels and effl uent solute 
levels would provide a more precise indication of control 
and represent a closer assessment for clearance. However, 
we did not measure effl uent biochemistry.
The study was conducted in a single tertiary level ICU, 
where training and expertise among nurses for their ability 
to troubleshoot alarm conditions may infl uence delivered 
time (12 hours) compared with other centres, where circuits 
may terminate prematurely due to low skill level, or where 
the delays in reinstitution of therapy may be due to poor 
training. One further limitation may be the defi ned BFR used 
in this study. We chose 150 mL/min and 250 mL/min as a 
result of current intensive care practices. BFRs < 150 mL/
min or > 250 mL/min may have yielded a different fi nding.
Conclusions
A BFR of 250 mL/min does not improve solute clearance 
compared with a BFR of 150 mL/min in CVVH or CVVHDF. 
Independent factors that affect solute removal include 
hours of effective treatment and haemoglobin levels.
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